Swedish biotechnology company Biotage $BIOT.ST has announced that private equity firm KKR has made a cash bid to acquire the company for approximately 11.6 billion Swedish kronor (around $1.22 billion). The offer, priced at 145 kronor per share, represents a significant premium of 60.1% compared to Biotage's closing share price on April 17. The company's board has unanimously recommended that shareholders accept the proposal, indicating strong support for the acquisition.